Efficacy and Safety of Sublingual Immunotherapy in Children Aged 3–13 Years with Allergic Rhinitis

Abstract

SLIT is effective and well-tolerated in children with allergic rhinitis 3-13 years old.

Chinese Guideline on allergen immunotherapy for allergic rhinitis

“…The findings of Marogna and colleagues (53) have been confirmed by a recent study which investigated the effects of SLIT on new sensitization in Chinese AR children aged 3-13 years (54). Assessment of the number of positive SPTs before and after treatment demonstrated that the onset of new sensitization was observed in only 3.55% of children treated by SLIT for 12 months compared with a significantly greater number of 27.27% of children treated by standard drug therapy.…”

“…The recommended optimal duration of AIT to achieve maximal efficacy with safety for AR in children is presently unclear. However, one recent study in China has demonstrated good tolerance and safety of SLIT in children as young as 3 years old with Der f-induced AR with or without asthma (54). Similarly, another study has reported good tolerance and safety of HDM-SCIT in over 5 years-old children with a history of HDM-induced AR or asthma (47).…”

“…All these studies demonstrated that the AIT treated group had a significant decline in the medication score compared with the placebo group (54,55,134,234).…”

“…The nocturnal asthma symptoms are scored from 0 to 4 points according to the frequency of nocturnal and early morning awakening by asthma. The total asthma symptom score (TASS) is the sum of daytime and nocturnal asthma symptoms scores, and generally been evaluated monthly in most studies (54,55,134,234,235).…”

Editorial: Insights into Disease Pathogenesis and Novel Therapeutics

“…Much attention has been paid to sublingual immunotherapy (SLIT) in recent years, but SLIT in the pediatric population is an area in need of further evidence. Here Shao et al 9 provide sorely needed data to indicate that even in children as young as 3 years of age, SLIT can be both safe and efficacious.…”